Synergistic antitumoral efficacy of a novel replicative adenovirus SG611-PDCD5 and daunorubicin in human leukemic cells
Open Access
- 1 August 2018
- journal article
- research article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 11, 5121-5132
Abstract
Background: Daunorubicin is a traditional chemotherapeutic agent that plays a pivotal role in leukemia therapy. However, the dose-related toxicity remains a considerable challenge. The apoptosis-regulating gene, PDCD5, is downregulated in various tumors, including leukemias, and may provide a potential target for the diagnosis and treatment of leukemia. The purpose of this study was to construct a triple-regulated oncolytic adenovirus carrying a PDCD5 gene expression cassette (SG611-PDCD5) and explore the combined antitumor efficacy of SG611-PDCD5 in combination with low dose daunorubicin on leukemic cells. Materials and methods: A variety of leukemic cell lines, including K562, MEG-01, KG-1a, HL-60, SUP-B15, and BV-173, were cultured according to the providers’ instructions. The insertion and orientation of all recombined plasmids were confirmed by restriction enzyme digestion and PCR. The tumor-selective replication of the constructed conditionally replicating SG611-PDCD5 and its antitumor efficacy in combination with daunorubicin were characterized in leukemic cell lines in vitro and in a nude mouse xenograft model. Cell viability was detected using cell-counting kit-8. Apoptosis was detected in whole living cells using flow cytometry and in paraffin-embedded tumor tissues using a terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay. Results: The triple-regulated CRAd carrying SG611-PDCD5 and nude mouse xenograft models of K562 cells were successfully constructed. In vitro treatment with SG611-PDCD5 in combination with low-dose daunorubicin elicited more potent anti-proliferative and proapoptotic effects in leukemic cells in a dose-dependent manner. The Chou-Talalay analysis revealed synergistic anti-proliferative effects in all of the above cell lines. In the nude mice xenograft model, the tumor size in the control, daunorubicin, SG611-PDCD5, and combined treatment groups on day 10 were 170.1±47.8, 111.9±81.1, 60.7±12.3, and 33.2±17.5 mm3, respectively (all PP Conclusion: The findings suggest that combined treatment with SG611-PDCD5 and daunorubicin may be a promising strategy for enhancing chemosensitivity and thus lowering the dose-related toxicity of daunorubicin in leukemia therapy.Keywords
This publication has 25 references indexed in Scilit:
- Cardiotoxicity of anthracycline therapy: current perspectivesArchives of Medical Science, 2016
- A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancersMolecular Cancer Therapeutics, 2008
- Bax gene therapy for human osteosarcoma using cationic liposomes in vivoOncology Reports, 2007
- Increased Safety with Preserved Antitumoral Efficacy on Hepatocellular Carcinoma with Dual-Regulated Oncolytic AdenovirusClinical Cancer Research, 2006
- Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemiaLeukemia Research, 2006
- Adenovirus-mediated TA-p73β gene transfer increases chemosensitivity of human malignant melanomasApoptosis, 2006
- Potent antitumoral efficacy of a novel replicative adenovirus CNHK300 targeting telomerase-positive cancer cellsJournal of Cancer Research and Clinical Oncology, 2004
- Synergistic chemosensitization and inhibition of tumor growth and metastasis by adenovirus-mediated p53 gene transfer in human bladder cancer modelUrology, 2000
- The Hallmarks of CancerCell, 2000
- The inhibitors of apoptosis (IAPs) and their emerging role in cancerOncogene, 1998